Cargando…

Targeting TRPM2 in ROS-Coupled Diseases

Under pathological conditions such as inflammation and ischemia-reperfusion injury large amounts of reactive oxygen species (ROS) are generated which, in return, contribute to the development and exacerbation of disease. The second member of the transient receptor potential (TRP) melastatin subfamil...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Shinichiro, Shimizu, Shunichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039510/
https://www.ncbi.nlm.nih.gov/pubmed/27618067
http://dx.doi.org/10.3390/ph9030057
_version_ 1782456071505313792
author Yamamoto, Shinichiro
Shimizu, Shunichi
author_facet Yamamoto, Shinichiro
Shimizu, Shunichi
author_sort Yamamoto, Shinichiro
collection PubMed
description Under pathological conditions such as inflammation and ischemia-reperfusion injury large amounts of reactive oxygen species (ROS) are generated which, in return, contribute to the development and exacerbation of disease. The second member of the transient receptor potential (TRP) melastatin subfamily, TRPM2, is a Ca(2+)-permeable non-selective cation channel, activated by ROS in an ADP-ribose mediated fashion. In other words, TRPM2 functions as a transducer that converts oxidative stress into Ca(2+) signaling. There is good evidence that TRPM2 plays an important role in ROS-coupled diseases. For example, in monocytes the influx of Ca(2+) through TRPM2 activated by ROS contributes to the aggravation of inflammation via chemokine production. In this review, the focus is on TRPM2 as a molecular linker between ROS and Ca(2+) signaling in ROS-coupled diseases.
format Online
Article
Text
id pubmed-5039510
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-50395102016-10-04 Targeting TRPM2 in ROS-Coupled Diseases Yamamoto, Shinichiro Shimizu, Shunichi Pharmaceuticals (Basel) Review Under pathological conditions such as inflammation and ischemia-reperfusion injury large amounts of reactive oxygen species (ROS) are generated which, in return, contribute to the development and exacerbation of disease. The second member of the transient receptor potential (TRP) melastatin subfamily, TRPM2, is a Ca(2+)-permeable non-selective cation channel, activated by ROS in an ADP-ribose mediated fashion. In other words, TRPM2 functions as a transducer that converts oxidative stress into Ca(2+) signaling. There is good evidence that TRPM2 plays an important role in ROS-coupled diseases. For example, in monocytes the influx of Ca(2+) through TRPM2 activated by ROS contributes to the aggravation of inflammation via chemokine production. In this review, the focus is on TRPM2 as a molecular linker between ROS and Ca(2+) signaling in ROS-coupled diseases. MDPI 2016-09-07 /pmc/articles/PMC5039510/ /pubmed/27618067 http://dx.doi.org/10.3390/ph9030057 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Yamamoto, Shinichiro
Shimizu, Shunichi
Targeting TRPM2 in ROS-Coupled Diseases
title Targeting TRPM2 in ROS-Coupled Diseases
title_full Targeting TRPM2 in ROS-Coupled Diseases
title_fullStr Targeting TRPM2 in ROS-Coupled Diseases
title_full_unstemmed Targeting TRPM2 in ROS-Coupled Diseases
title_short Targeting TRPM2 in ROS-Coupled Diseases
title_sort targeting trpm2 in ros-coupled diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039510/
https://www.ncbi.nlm.nih.gov/pubmed/27618067
http://dx.doi.org/10.3390/ph9030057
work_keys_str_mv AT yamamotoshinichiro targetingtrpm2inroscoupleddiseases
AT shimizushunichi targetingtrpm2inroscoupleddiseases